ArriVent BioPharma (AVBP) Income from Continuing Operations (2023 - 2026)

ArriVent BioPharma has disclosed Income from Continuing Operations across 4 years of filings, most recently posting 43320000.0 for Q1 2026.

• Income from Continuing Operations for Q1 2026 came in at 43320000.0, up 32.72% year-over-year; the trailing twelve-month figure through Mar 2026 was 145241000.0 (down 13.95% YoY), and the FY2025 annual result was 166308000.0, down 106.62% from the prior year.
• Income from Continuing Operations came in at 43320000.0 for Q1 2026 at ArriVent BioPharma, down from 35544000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 12172000.0 in Q1 2023 to a low of 64387000.0 in Q1 2025.
• The 4-year median for Income from Continuing Operations is 21567000.0 (2023), against an average of 27649923.08.
• Across the five-year window, Income from Continuing Operations tumbled 269.68% in 2025 and soared 32.72% in 2026, its largest moves.
• ArriVent BioPharma's Income from Continuing Operations stood at 21193000.0 in 2023, then rose by 2.64% to 20633000.0 in 2024, then tumbled by 72.27% to 35544000.0 in 2025, then declined by 21.88% to 43320000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 43320000.0 (Q1 2026), 35544000.0 (Q4 2025), and 34978000.0 (Q3 2025), per Business Quant data.